Mycoses

Papers
(The H4-Index of Mycoses is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
COVID‐19 associated pulmonary aspergillosis410
COVID‐19‐associated mucormycosis: An updated systematic review of literature167
Invasive pulmonary aspergillosis in the COVID‐19 era: An expected new entity135
COVID‐19‐associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID‐19 pneumonia: An observational study from Pakistan124
ECMM/ISHAM recommendations for clinical management of COVID‐19 associated mucormycosis in low‐ and middle‐income countries124
The double‐edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza‐associated mucormycosis versus COVID‐19 associated mucormycosis124
Alarming India‐wide phenomenon of antifungal resistance in dermatophytes: A multicentre study116
Increased incidence of candidemia in a tertiary care hospital with the COVID‐19 pandemic109
Mucormycosis and COVID‐19: An epidemic within a pandemic in India107
Oropharyngeal candidiasis in hospitalised COVID‐19 patients from Iran: Species identification and antifungal susceptibility pattern97
Mucormycosis in patients with COVID‐19: A cross‐sectional descriptive multicentre study from Iran94
Breakthrough invasive fungal infections: Who is at risk?92
Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis: A systematic review and meta‐analysis71
Characteristics of candidemia in COVID‐19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non‐COVID‐19 patients59
Prevalence of opportunistic invasive aspergillosis in COVID‐19 patients with severe pneumonia58
Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k)53
Epidemiology and Mycology of Candidaemia in non‐oncological medical intensive care unit patients in a tertiary center in the United States: Overall analysis and comparison between non‐COVID‐19 and COV46
COVID‐19–associated pulmonary aspergillosis: a prospective single‐center dual case series45
Isolation of Aspergillus spp. in respiratory samples of patients with COVID‐19 in a Spanish Tertiary Care Hospital45
Invasive aspergillosis in critically ill patients: Review of definitions and diagnostic approaches44
Changes in the relative prevalence of candidaemia due to non‐albicans Candida species in adult in‐patients: A systematic review, meta‐analysis and meta‐regression40
Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope® registry40
Accuracy of galactomannan testing on tracheal aspirates in COVID‐19‐associated pulmonary aspergillosis39
Treatment of invasive fungal diseases in cancer patients—Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)38
Axillary Digital Thermometers uplifted a multidrug‐susceptible Candidaauris outbreak among COVID‐19 patients in Brazil37
Invasive dermatophyte infection: A systematic review37
Results from a national survey on COVID‐19‐associated mucormycosis in Germany: 13 patients from six tertiary hospitals37
Fluconazole‐resistant Candida parapsilosis strains with a Y132F substitution in the ERG11 gene causing invasive infections in a neonatal unit, South Africa33
Increased incidence of rhino‐orbital mucormycosis in an educational therapeutic hospital during the COVID‐19 pandemic in western Iran: An observational study33
Global prevalence and subgroup analyses of coronavirus disease (COVID‐19) associated Candida auris infections (CACa): A systematic review and meta‐analysis32
Is there an association between zinc and COVID‐19–associated mucormycosis? Results of an experimental and clinical study32
0.048239946365356